| Recruiting | Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Ca NCT07485114 | Daniel Keizman | — |
| Terminated | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib NCT05052372 | xCures | — |
| Unknown | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder NCT04878250 | Queen Mary University of London | Phase 2 |
| Active Not Recruiting | CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood NCT04811846 | University Teaching Hospital Hall in Tirol | N/A |
| Active Not Recruiting | BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer NCT06462001 | Nottingham University Hospitals NHS Trust | Phase 3 |
| Withdrawn | Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint I NCT04179110 | Yale University | Phase 2 |
| Withdrawn | Efficacy and Safety of UGN-101 in Recurrent Patients NCT04006691 | UroGen Pharma Ltd. | Phase 3 |
| Terminated | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PS NCT03927573 | AvenCell Europe GmbH | Phase 1 |
| Unknown | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor NCT03896958 | SpeciCare | — |
| Withdrawn | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of M NCT03238664 | University of Southern California | N/A |
| Unknown | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carci NCT03219775 | AIO-Studien-gGmbH | Phase 2 |
| Active Not Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced NCT02887248 | SCRI Development Innovations, LLC | Phase 2 |
| Unknown | Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemother NCT03193788 | Asan Medical Center | Phase 3 |
| Completed | Detecting Transitional Cell Carcinoma From Haematuria NCT03256877 | Hull University Teaching Hospitals NHS Trust | — |
| Unknown | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma NCT03296306 | Asan Medical Center | Phase 3 |
| Completed | Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer NCT02581982 | Wake Forest University Health Sciences | Phase 2 |
| Unknown | Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT NCT02471547 | Sheba Medical Center | N/A |
| Active Not Recruiting | Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothe NCT02420847 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Alisertib in Chemotherapy-pretreated Urothelial Cancer NCT02109328 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial NCT02160600 | All India Institute of Medical Sciences | N/A |
| Terminated | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer NCT01438112 | CG Oncology, Inc. | Phase 2 / Phase 3 |
| Completed | Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel NCT01668459 | Dr Anjali Zarkar | Phase 2 / Phase 3 |
| Completed | Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer NCT01395225 | University of British Columbia | — |
| Terminated | Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Mainte NCT01310803 | Endo Pharmaceuticals | Phase 3 |
| Terminated | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma NCT01215136 | Matthew Galsky | Phase 2 |
| Terminated | Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomyci NCT01200992 | Bioniche Life Sciences Inc. | Phase 3 |
| Completed | JAVLOR® Online Non-Interventional Trial NCT01103544 | Pierre Fabre Pharma GmbH | — |
| Completed | A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients Wit NCT00714025 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Completed | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types NCT00633789 | Bristol-Myers Squibb | Phase 2 |
| Withdrawn | Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer NCT00696007 | Lahey Clinic | Phase 2 |
| Completed | Single Agent Abraxane as Second Line Therapy in Bladder Cancer NCT00683059 | Sunnybrook Health Sciences Centre | Phase 2 |
| Completed | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen NCT00623831 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible NCT00389155 | Bristol-Myers Squibb | Phase 2 / Phase 3 |
| Completed | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC NCT00880334 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Relationship of Ochratoxin A to Upper Urologic Cancers NCT00216801 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | — |
| Completed | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium NCT00101608 | Bristol-Myers Squibb | Phase 2 |
| Completed | Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagn NCT00612326 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas NCT00070070 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | Weekly TP-HDFL in the Treatment of Advanced TCC NCT00154687 | National Taiwan University Hospital | Phase 2 |
| Completed | Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC NCT00173862 | National Taiwan University Hospital | Phase 2 |